戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 mune blistering skin diseases, pemphigus and bullous pemphigoid.
2 dase-IV inhibitor-associated noninflammatory bullous pemphigoid.
3 ermal blistering disease that closely mimics bullous pemphigoid.
4 associated with the blistering skin disease, bullous pemphigoid.
5 e relevant in the diagnosis and treatment of bullous pemphigoid.
6 pemphigoid and help distinguishing them from bullous pemphigoid.
7  as valuable medications in the treatment of bullous pemphigoid.
8 sh nomacopan as a new therapeutic option for bullous pemphigoid.
9 nd for the clinical benefit of patients with bullous pemphigoid.
10 ut blisters had immunopathologic findings of bullous pemphigoid.
11 hout skin lesions can be the only symptom of bullous pemphigoid.
12 en of the autoimmune skin blistering disease bullous pemphigoid.
13 s in a mouse model of the autoimmune disease bullous pemphigoid.
14 in NC16A are involved in the pathogenesis of bullous pemphigoid.
15 he development of the autoimmune response in bullous pemphigoid.
16 .2% female; specifically, 6951 patients with bullous pemphigoid, 1669 patients with pemphigus, and 79
17 ibodies directed against the NC16A domain of bullous pemphigoid 180 (collagen XVII), a transmembrane
18 s that bind to this immunodominant region of bullous pemphigoid 180 are capable of inducing a skin di
19 d patients, all of whom had circulating anti-bullous pemphigoid 180 autoantibodies, showed a specific
20 correlations were seen with desmoglein 1 and bullous pemphigoid 180 titers.
21 nic target of autoantibodies associated with bullous pemphigoid, a blistering skin disease.
22 mice would also be resistant to experimental bullous pemphigoid, a disease with a pathogenesis though
23 ned autoantibody-reactive site recognized by bullous pemphigoid and herpes gestationis sera) and the
24 th two other autoimmune blistering diseases, bullous pemphigoid and herpes gestationis.
25 can be well tolerated in older patients with bullous pemphigoid and may have therapeutic benefits for
26 ednisolone for short-term blister control in bullous pemphigoid and significantly safer in the long-t
27 nths (lichenoid dermatitis), and 5-6 months (bullous pemphigoid and vitiligo).
28 e dermal-epidermal-junction is a hallmark of bullous pemphigoid and was shown to be important for pat
29 , pemphigus foliaceous, pemphigus, vulgaris, bullous pemphigoid, and benign chronic pemphigus, howeve
30  lupus erythematosus, angioedema, pemphigus, bullous pemphigoid, and HS.
31 vulgaris were diagnosed; there was 1 case of bullous pemphigoid; and 1 suspected case of paraneoplast
32                       These mice represent a bullous pemphigoid animal model featuring pruritus in im
33 esmosomal transmembrane protein, the 180 kDa bullous pemphigoid antigen (BP180), also known as type X
34 n utilizing primers specific for the 230 kDa bullous pemphigoid antigen (BPAG1), the 180 kDa bullous
35                                  The 180-kDa bullous pemphigoid antigen (BPAG2) is a candidate gene/p
36 lous pemphigoid antigen (BPAG1), the 180 kDa bullous pemphigoid antigen (BPAG2), the alpha6 and beta4
37 mma, activated the skin-specific promoter of bullous pemphigoid antigen 1 (BPAG-1).
38                                              Bullous pemphigoid antigen 1 (BPAG1) is a member of the
39                                              Bullous pemphigoid antigen 1 (BPAG1) is a member of the
40  They contain mutations in the gene encoding Bullous Pemphigoid Antigen 1 (BPAG1), or dystonin.
41                                              Bullous pemphigoid antigen 1 (BPAG1-e, also known as BP2
42  and is identical to the neuronal isoform of bullous pemphigoid antigen 1 (BPAG1-n).
43                       Other plakins, such as bullous pemphigoid antigen 1 and microtubule and actin c
44                     Disruption of the BPAG1 (bullous pemphigoid antigen 1) gene results in progressiv
45  proteins, to which envoplakin, desmoplakin, bullous pemphigoid antigen 1, and plectin belong.
46 led-coil domain of the epithelial isoform of bullous pemphigoid antigen 1, BPAG1-e (also known as BP2
47 gnized desmoplakin and plectin, and, weakly, bullous pemphigoid antigen 1.
48        Autoreactive T cells to an epitope of bullous pemphigoid antigen 180 kilodaltons were identifi
49 he beta4 integrin-associated plakin protein, bullous pemphigoid antigen 1e (BPAG1e) functions as a sc
50  integrin or knockdown of the plakin protein Bullous Pemphigoid Antigen 1e (BPAG1e).
51                                              Bullous pemphigoid antigen 2 (BPAG2) is targeted by auto
52       Skin grafts from mice expressing human bullous pemphigoid antigen 2 (hBPAG2) in epidermal basem
53 5 (p < 0.05), and in skin from patients with bullous pemphigoid antigen 2 mutations (n = 3) the count
54 roteins such as the integrin alpha6beta4 and bullous pemphigoid antigen 2 within the hemidesmosomes a
55 D97 is a component of the shed ectodomain of bullous pemphigoid antigen 2.
56 s reduced dynamics, and fails to recruit its bullous pemphigoid antigen binding partners.
57                                          The bullous pemphigoid antigen BPAG1 is required for keratin
58 ression of zinc finger protein 185 (ZNF185), bullous pemphigoid antigen gene (BPAG1), and prostate se
59  and attest to the importance of the 180-kDa bullous pemphigoid antigen in the attachment of the epid
60                                     A second bullous pemphigoid antigen of 180 kDa (BP180/BPAG2) is a
61 roteins and include desmoplakin, the 230 kDa bullous pemphigoid antigen, and envoplakin.
62  protein interacting with Nck (SPIN90/WISH), bullous pemphigoid antigen-1, and calcium channel beta2.
63 s of BMZ proteins: one enriched with the two bullous pemphigoid antigens (BP230, BP180) and one enric
64 he alpha6beta4 integrin, plectin, and BPAGs (bullous pemphigoid antigens).
65                                Pemphigus and bullous pemphigoid are autoantibody-mediated blistering
66                                Pemphigus and bullous pemphigoid are distinct autoimmune blistering di
67 n that contains all four of the well-defined bullous pemphigoid-associated antigenic sites.
68 has recently demonstrated that reactivity of bullous pemphigoid autoantibodies to the BP180 ectodomai
69 tandard techniques for detecting circulating bullous pemphigoid autoantibodies, including other enzym
70 h the 180 and 230 kDa proteins recognized by bullous pemphigoid autoantibodies, LABD97 has been thoug
71 t of the hemidesmosome plaque is the 230-kDa bullous pemphigoid autoantigen (BP230/BPAG1), which conn
72  salt-split indirect immunofluorescence, and bullous pemphigoid (BP) 230 and BP180-NC16A ELISAs.
73 tween serum levels of autoantibodies against bullous pemphigoid (BP) antigens 180 (BP180) and 230 (BP
74                            Autoantibodies in bullous pemphigoid (BP) are known to activate the innate
75 munofluorescence, and specific reactivity to bullous pemphigoid (BP) autoantigens BP180 and BP230, co
76 Affiliated Hospitals with a new diagnosis of bullous pemphigoid (BP) between May 1, 1997 and Septembe
77                                              Bullous pemphigoid (BP) has been previously described to
78            Although predisposing factors for bullous pemphigoid (BP) have been recently established,
79                                              Bullous pemphigoid (BP) is a bullous dermatosis associat
80                                      De novo bullous pemphigoid (BP) is a rare immune-mediated advers
81                                              Bullous pemphigoid (BP) is a subepidermal blistering dis
82                                              Bullous pemphigoid (BP) is a subepidermal blistering dis
83                                              Bullous pemphigoid (BP) is a subepidermal blistering dis
84                                              Bullous pemphigoid (BP) is an autoantibody-mediated blis
85                                              Bullous pemphigoid (BP) is an autoimmune bullous disease
86                                              Bullous pemphigoid (BP) is an autoimmune disease associa
87                                              Bullous pemphigoid (BP) is an autoimmune disease charact
88                                              Bullous pemphigoid (BP) is an autoimmune skin disease ch
89                                              Bullous pemphigoid (BP) is an autoimmune skin disease ch
90                                              Bullous pemphigoid (BP) is an autoimmune skin disease ch
91                                              Bullous pemphigoid (BP) is an autoimmune skin-blistering
92                                              Bullous pemphigoid (BP) is an autoimmune subepidermal bl
93                                              Bullous pemphigoid (BP) is an autoimmune subepidermal bl
94                                              Bullous pemphigoid (BP) is an autoimmune subepidermal bl
95                                              Bullous pemphigoid (BP) is an inflammatory subepidermal
96                                              Bullous pemphigoid (BP) is an inflammatory subepidermal
97                                              Bullous pemphigoid (BP) is by far the most frequent auto
98                                              Bullous pemphigoid (BP) is characterized by the depositi
99 tibodies from the sera of some patients with bullous pemphigoid (BP) react with a 180 kDa protein ter
100                          Studies have linked bullous pemphigoid (BP) with venous thromboembolism (VTE
101                                              Bullous pemphigoid (BP), a common autoimmune blistering
102 ation has long been a histologic hallmark of bullous pemphigoid (BP), a subepidermal autoimmune blist
103 ermal separation in an experimental model of bullous pemphigoid (BP), an autoimmune disease.
104  targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one
105  sera from patients with pemphigus vulgaris, bullous pemphigoid (BP), and chronic atopic and chronic
106 tients with a blistering skin disease called bullous pemphigoid (BP), is a transmembrane component of
107 rom patients with MMP, 1 of 50 patients with bullous pemphigoid (BP), none of 7 with pemphigus, and 3
108 e used IgG passive transfer murine models of bullous pemphigoid (BP), pemphigus foliaceus (PF), and p
109                               The outcome of bullous pemphigoid (BP), the most frequent autoimmune sk
110                                              Bullous pemphigoid (BP), the most frequent blistering de
111 eurological disorders may be associated with bullous pemphigoid (BP).
112  reported sequence of the 180 kDa antigen in bullous pemphigoid (BPAg2).
113 ns regarding an experimental murine model of bullous pemphigoid by showing that the plasminogen/plasm
114                                              Bullous pemphigoid cases also more frequently exhibited
115 heir first year of life, with uncontrollable bullous pemphigoid, colitis, and proteinuria.
116 th BP underwent clinical evaluation with the Bullous Pemphigoid Disease Activity Index (BPDAI); and 3
117  mean absolute and percentage changes in the Bullous Pemphigoid Disease Area Index (BPDAI) activity s
118 d diagnosis of pemphigus vulgaris/foliaceus, bullous pemphigoid, epidermolysis bullosa acquisita, muc
119 tream from the MCW-1 domain, the predominant bullous pemphigoid epitope.
120             In the literature, patients with bullous pemphigoid have been reported to have itch witho
121 usion, there are now three bullous diseases, bullous pemphigoid, herpes gestationis, and cicatricial
122 , vitiligo (HR, 0.534; 95% CI, 0.254-1.123), bullous pemphigoid (HR, 0.524; 95% CI, 0.140-1.956), and
123 eports, including vitiligo (IC(025) = 4.87), bullous pemphigoid (IC(025) = 4.08), lichenoid dermatiti
124 ation on immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) in patients with cancer, wit
125 ded, that is, chronic spontaneous urticaria, bullous pemphigoid, IgA (Henoch-Schonlein purpura) and I
126                                              Bullous pemphigoid is a blistering skin disease characte
127                                              Bullous pemphigoid is a blistering skin disorder with in
128                                              Bullous pemphigoid is a chronic, subepidermal autoimmune
129                                              Bullous pemphigoid is a difficult-to-treat autoimmune bl
130                             The incidence of bullous pemphigoid is increasing, attributed to an agein
131 l patients with immunopathologic findings of bullous pemphigoid, itch, and no blisters.
132 e toxin-1-positive S. aureus is prevalent in bullous pemphigoid lesions and suggests that early imple
133 . aureus colonization was observed in 85% of bullous pemphigoid lesions, 3-6-fold higher than the nar
134 . aureus colonization was observed in 85% of bullous pemphigoid lesions, 3-6-fold higher than the nar
135                         In the inflammatory (bullous pemphigoid-like) EBA variant, autoantibody bindi
136 systemic lupus erythematosus (BSLE) (n = 3), bullous pemphigoid (n = 16), pemphigus (n = 11), and nor
137    Pemphigus vulgaris (n=40, USA and Japan), bullous pemphigoid (n=40, USA), and healthy donors (n=55
138 nhibitor, in 10 subjects with active or past bullous pemphigoid (NCT02502903).
139 skin disorders, including atopic dermatitis, bullous pemphigoid, Netherton's syndrome, and prurigo no
140          Immune checkpoint inhibitor-induced bullous pemphigoid often occurred during the course of a
141 ostic assays and expertise and classified as bullous pemphigoid or epidermolysis bullosa acquisita.
142 ovide a source of infection in patients with bullous pemphigoid, particularly in the setting of high-
143 stemic lupus erythematosus patients (n = 3), bullous pemphigoid patients (n = 15), and normal humans
144                     T cells from eight of 12 bullous pemphigoid patients, all of whom had circulating
145 sease-specific autoantibodies in the sera of bullous pemphigoid patients.
146 e examined the autoimmune T cell response in bullous pemphigoid patients.
147                      Sera from patients with bullous pemphigoid, pemphigus vulgaris, and cicatricial
148 reas the predominant epitope identified with bullous pemphigoid sera is located in the noncollagenous
149                      Of 50 randomly selected bullous pemphigoid sera tested, 47 (94%) were positive i
150              Interestingly, all three of the bullous pemphigoid sera that were negative in this assay
151  inducing a skin disease that closely mimics bullous pemphigoid, supporting the hypothesis that epito
152 icture may be indistinguishable from that of bullous pemphigoid, the latter being the most common aut
153 p randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or mor
154 sults with a complement-targeting therapy in bullous pemphigoid, to our knowledge, and supports furth
155 mmon in elderly patients, including scabies, bullous pemphigoid, transient acantholytic dermatosis, a
156 sociated dermatoses (e.g. atopic dermatitis, bullous pemphigoid, urticaria).
157 A potential role of Staphylococcus aureus in bullous pemphigoid was explored by examining the coloniz
158  (median [range] age, 75 [55-85] years) with bullous pemphigoid were included in the trial, of whom 5
159 ith mild to moderate, new-onset or relapsing bullous pemphigoid were recruited into the study.
160   Earlier preliminary studies in humans with bullous pemphigoid, which is also associated with excess
161         The most common of these diseases is bullous pemphigoid, which mainly affects older people an

 
Page Top